Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”),
through its wholly-owned subsidiary Emblem Cannabis Corporation,
today announced the launch of a new line of 10mg Emblem Oil
Capsules, providing its growing list of 6,000+ patients with a
pre-dosed treatment format. This convenient capsule formulation is
designed to help patients better manage their treatment through
precise dosing of their cannabis medication.
“Patient-focused treatment options are key drivers of Emblem’s
innovation pipeline. As a patient-first provider, we’re continuing
to develop products that meet our patients’ needs now and into the
future,” said Nick Dean, CEO, Emblem Corp. “Accessing a variety of
distribution channels is also a critical factor in our business
strategy, and we are pleased to offer our medical cannabis products
direct to patients through www.emblemcannabis.com, and soon through
our supply agreement with Shoppers Drug Mart, which recently
received its Federal Medical Sales License.”
“Patients want access to medical cannabis in formats that are
discreet and easy-to-use, with established dosing,” added Wayne
Kreppner, President of Medical, Emblem Corp. “The precision found
in Emblem’s Oil Capsules addresses this and allows patients to
easily track their medication and adjust as needed, while giving
healthcare professionals another mode of administration that
resembles traditional medications.”
The 10mg Emblem Oil Capsules offer a consistent patient
experience formulated with three chemovar specific formats - High
THC (10mg THC per capsule), High CBD (10 mg CBD per capsule) and
Balanced (6mg THC/10 mg CBD per capsule). The capsules are
odorless, flavourless and vegan, and suitable for patients already
established on a cannabis oil dosage of 10mg or more. Patients
can expect the same high quality in the Emblem Oil Capsules as
found in the rest of Emblem's line of oil products, which includes
Atmosphere oral dose-metered sprays and Emblem Oils.
Emblem plans to introduce additional dosage strengths of its oil
capsules in the coming months to further address the medical needs
of new patients or those wishing to titrate their dosage.
Shares Outstanding The Company would also like
to note that the total number of issued and outstanding shares in
the Company’s MD&A for the nine-month period ended September
30, 2018 referenced 123,606,221 common shares issued and
outstanding as of the date of the filing of such MD&A. This
number did not reflect the 6,952,169 shares issued to Aphria as was
set out in the Company’s September 12, 2018 news release. As
such, as of the date of the Company’s MD&A for the period ended
September 30, 2018, the total issued and outstanding shares should
have read 130,558,390 – such number also being the number of issued
and outstanding shares as of the date of this news release.
Appointment of Officers Emblem has
formally appointed two new officers of the Company – Maria Guest,
Chief Marketing Officer, and Karyn Sullivan, General Counsel &
Secretary, both of whom joined Emblem earlier this
year.
About Emblem Emblem is a fully integrated
cannabis company focused on driving shareholder value through
product innovation, brand relevance, and access to patient and
consumer channels. Through its wholly-owned subsidiary Emblem
Cannabis Corporation, Emblem is licensed to cultivate, process, and
sell cannabis and cannabis derivatives in Canada under
the Cannabis Act. Emblem’s state-of-the-art indoor cannabis
cultivation facility and Product Innovation Centre is located in
Paris, Ontario. Emblem is also the parent company of GrowWise
Health Limited, one of Canada’s leading cannabis education
services. Emblem trades under the ticker symbol EMC on the TSX
Venture Exchange.
For more information, please
visit www.emblemcorp.com.
For media inquiries, please contact:Morgan
Cates H+K Strategies 416.413.4649 Morgan.cates@hkstrategies.ca
For investor inquiries, please contact:Ethan
Karayannopoulos Investor Relations Emblem Corp. 647.748.9696
ethank@emblemcorp.com
Alex Stojanovic Chief Financial Officer Emblem Corp.
416.923.1331 alexs@emblemcorp.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATIONThis
news release contains certain forward-looking statements and
forward-looking information (collectively referred to herein as
“forward-looking statements”) within the meaning of applicable
Canadian securities laws. All statements other than statements of
present or historical fact are forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as “anticipate”, “achieve”, “could”,
“believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”,
“estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should”
or similar words, including negatives thereof, suggesting future
outcomes. Management of the Company believes the expectations
reflected in such forward-looking statements are reasonable as of
the date hereof but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon. Various material
factors and assumptions are typically applied in drawing
conclusions or making the forecasts or projections set out in
forward-looking statements. Those material factors and assumptions
are based on information currently available to the Company,
including data from publicly available governmental sources as well
as from market research and industry analysis and on assumptions
based on data and knowledge of this industry which Emblem believes
to be reasonable. However, although generally indicative of
relative market positions, market shares and performance
characteristics, such data is inherently imprecise. While Emblem is
not aware of any misstatement regarding any industry or government
data presented herein, the medical marijuana industry involves
risks and uncertainties and is subject to change based on various
factors.
Forward-looking statements are not a guarantee of future
performance and are subject to and involve a number of known and
unknown risks and uncertainties, many of which are beyond the
control of the Company, which may cause the Company’s actual
performance and results to differ materially from any projections
of future performance or results expressed or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks identified in the Company’s
December 31, 2017 Management’s Discussion and Analysis, which has
been filed with the Canadian Securities Administrators and
available on www.sedar.com. Any forward-looking statements are made
as of the date hereof and, except as required by law, the Company
assumes no obligation to publicly update or revise such statements
to reflect new information, subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Emblem Corp (TSXV:EMC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emblem Corp (TSXV:EMC)
Historical Stock Chart
From Apr 2023 to Apr 2024